Why don't we initiate more large simple randomized controlled trials?
Wright
James M
JM
Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC. jmwright@interchange.ubc.ca
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy; D002170:Canada; D000068579:Celecoxib; D003257:Consumer Product Safety / Q000592:standards; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000592:standards; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib